The next treatment-resistant depression paradigm

Treatment-resistant depression (TRD) stems from the inherent biological heterogeneity of major depressive disorder, rendering traditional monoaminergic therapies ineffective for a significant patient subset. Current treatment paradigms rely on repetitive, daily medication, which often fails to address the underlying complexity of the condition. Emerging interventions, such as NMDA receptor modulators and psilocybin therapy, offer a shift toward rapid-acting, durable efficacy that may reduce the long-term burden on patients and caregivers. Clinical evidence suggests that delaying these advanced treatments until late-stage lines of therapy exacerbates patient suffering and reduces the likelihood of recovery. Integrating novel, mechanism-differentiated approaches earlier in the treatment course, rather than relying on iterative variations of existing antidepressants, represents a critical evolution in psychiatric care aimed at restoring patient quality of life.